Improves Chronic Kidney Disease by Affecting TLR4/NF-B Redox Signaling Pathway.

may show good promise in protecting against chronic kidney disease (CKD) but the molecular mechanism remains unclear. CKD risk is associated with the Toll-like receptor 4/nuclear factor-kappa B (TLR4/NF-B) signaling pathway. Cordycepin is the main component of and may affect the TLR4/NF-B pathway. Cordycepin was prepared by preparative HPLC. CKD patients were assigned into (COG, 100 mg daily) and placebo (CG) groups. Cordycepin activity was measured using human embryo kidney cells (HEK293T). Biochemical indices, the levels of TLR4, NF-B, cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-), and interleukin-1 beta (IL-1), were measured by real-time qRT-PCR, or ELISA kits and or Western blot. After 3-month treatment, cordycepin reduced the levels of urinal protein, blood urea nitrogen (BUN), and creatinine by 36.7%±8.6%, 12.5%±3.2%, and 18.3%±6.6%, respectively ( < 0.05). improved lipid profile and redox capacity of CKD patients by reducing the serum levels of TG, TC, and LDL-C by 12.8%±3.6%, 15.7%±4.1%, and 16.5%±4.4% and increasing the HDL-C level by 10.1%±1.4% in the COG group when compared with the CG group, respectively ( < 0.05). The serum levels of cystatin-C (Cys-C), myeloperoxidase (MPO), and malondialdehyde (MDA) were reduced by 14.0%±3.8%, 26.9%±12.3%, and 19.7%±7.9% while nitric oxide (NO) and superoxide dismutase (SOD) were increased by 12.5%±2.9% and 25.3%±13.4% in the COG group when compared with the CG group, respectively ( < 0.05). Cordycepin reduced the levels of TLR4, NF-B, COX2, TNF-, and IL-1 in HEK293T cells too ( < 0.05). However, cordycepin could not affect the levels anymore if TLR4 was silenced. protected against CKD progression by affecting the TLR4/NF-B lipid and redox signaling pathway via cordycepin.